4th Annual Oncolytic Virotherapy (OV) Summit 2018
In-Person Event
Dec 04 - 06, 2018
Boston, Massachusetts, USA
OVERVIEW
4th Annual Oncolytic Virotherapy (OV) Summit is organized by Hanson Wade and will be held from Dec 04 - 06, 2018 at Hilton Boston Back Bay, Boston, Massachusetts, United States of America.
As many oncolytic viruses progress through the clinical pipelines, drug developers need to ensure that their therapies are safe, efficacious and commercially viable. Make sure you stay ahead of the game and join Oncolytic Virotherapy Summit, where you will have an opportunity to pick the brains of 100 senior industry peers and tackle your challenges in discovery, clinical development, manufacturing and regulations of oncolytic virotherapy.
Successful Late-stage Clinical Development:
Connect with experts that have been through late-stage development of oncolytic viruses to understand the key challenges and lessons learned. Learn how to translate an academic, early-stage product into commercial therapeutics ready for large-scale clinical trials.
Improve Treatment Efficacy with Combination Therapies:
Maximize the potential for using oncolytic viruses in combination by discussing combinations with; adoptive cell therapy, DNA damage response drugs, current frontline cancer therapies and many more strategies for rational combinations to enhance the efficacy of treatments.
Ensure Commercial Scale Manufacturing:
With limited external expertise and expensive options to build in-house facilities, the industry needs to invest early to grow and develop commercial-grade GMP facilities. Experts will share with you their case studies, capabilities and future strategies to ensure the commercial viability of oncolytic viruses to meet patient demand.
Speakers:
Grant McFadden, Center Director & Professor, Biodesign Center for Immunotherapy, ASU, Masataka Suzuki, Assistant Professor, Baylor College of Medicine, Brad Nelson, Director, Deeley Research Centre BC Cancer Agency, Frank Tufaro, CEO, DNAtrix, Antonio Chiocca, Professor, Harvard Medical School, Faris Farassati, Associate Professor, University of Kansas Medical School, Angelica Loskog, CEO, Lokon Pharma, Rachel Altura, Senior Medical Director, Merck & Co., Christophe Queva, Chief Scientific Officer, Oncorus, Steven Potts, CEO, OncoMyx, Robert Coffin, CEO, Replimmune, Anna Cascante, Head of R&D, Sagetis Biotech, Magnus Jaderberg, CMO, Targovax, Min Liang, CSO, TOT biopharma, José Manuel Otero, Vice President, CMC & Manufacturing, Turnstone Biologics, Daniel Katzman, Chief Executive Officer, Unleash Immuno Oncolytics, Stephen Thorne, Chief Scientific Officer, Western Oncolytics, William Jia, Chief Scientific Officer, Virogen
Additional details will be posted as soon as they are available.
As many oncolytic viruses progress through the clinical pipelines, drug developers need to ensure that their therapies are safe, efficacious and commercially viable. Make sure you stay ahead of the game and join Oncolytic Virotherapy Summit, where you will have an opportunity to pick the brains of 100 senior industry peers and tackle your challenges in discovery, clinical development, manufacturing and regulations of oncolytic virotherapy.
Successful Late-stage Clinical Development:
Connect with experts that have been through late-stage development of oncolytic viruses to understand the key challenges and lessons learned. Learn how to translate an academic, early-stage product into commercial therapeutics ready for large-scale clinical trials.
Improve Treatment Efficacy with Combination Therapies:
Maximize the potential for using oncolytic viruses in combination by discussing combinations with; adoptive cell therapy, DNA damage response drugs, current frontline cancer therapies and many more strategies for rational combinations to enhance the efficacy of treatments.
Ensure Commercial Scale Manufacturing:
With limited external expertise and expensive options to build in-house facilities, the industry needs to invest early to grow and develop commercial-grade GMP facilities. Experts will share with you their case studies, capabilities and future strategies to ensure the commercial viability of oncolytic viruses to meet patient demand.
Speakers:
Grant McFadden, Center Director & Professor, Biodesign Center for Immunotherapy, ASU, Masataka Suzuki, Assistant Professor, Baylor College of Medicine, Brad Nelson, Director, Deeley Research Centre BC Cancer Agency, Frank Tufaro, CEO, DNAtrix, Antonio Chiocca, Professor, Harvard Medical School, Faris Farassati, Associate Professor, University of Kansas Medical School, Angelica Loskog, CEO, Lokon Pharma, Rachel Altura, Senior Medical Director, Merck & Co., Christophe Queva, Chief Scientific Officer, Oncorus, Steven Potts, CEO, OncoMyx, Robert Coffin, CEO, Replimmune, Anna Cascante, Head of R&D, Sagetis Biotech, Magnus Jaderberg, CMO, Targovax, Min Liang, CSO, TOT biopharma, José Manuel Otero, Vice President, CMC & Manufacturing, Turnstone Biologics, Daniel Katzman, Chief Executive Officer, Unleash Immuno Oncolytics, Stephen Thorne, Chief Scientific Officer, Western Oncolytics, William Jia, Chief Scientific Officer, Virogen
Additional details will be posted as soon as they are available.
KEY DATES
04 Dec, 2018
Event Start Date
06 Dec, 2018
Event End Date
SPECIALITIES
OncologyInfectious DiseaseBiotechnologySUGGESTED HOTELS
CONFERENCE VENUE
Hilton Boston Back BayRELATED CONFERENCES & LIVE WEBINARS
Quick Links